Katarina Leckova, MD
Hematology & Oncology · Goshen, INNPI 1699734251
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,126 of the $5,331 with a category attached, or 77.4%. It is spread thinly across 38 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,163 and has fallen 84.1% since, to $343 in 2025.
Across 259 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$807
- E.r. Squibb & Sons, L.L.C.$720
- Pfizer$608
- Novartis$402
- Tempus AI, Inc$291
- AstraZeneca$285
- plus $2K from 32 others
Across 5 payments — averaging $1695.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$4K
- Jazz Pharmaceuticals Inc.$3K
- Amgen$2K
What the payments were for
- Food & beverage$4,12677%
- Education$1,20523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 15 | $807 |
| E.r. Squibb & Sons, L.L.C. | 53 | $720 |
| Pfizer | 38 | $608 |
| Novartis | 20 | $402 |
| Tempus AI, Inc | 13 | $291 |
| AstraZeneca(2 entities) | 15 | $285 |
| Merck | 16 | $270 |
| Lilly USA, LLC | 10 | $268 |
| Amgen | 12 | $261 |
| Sanofi | 10 | $187 |
| Genentech USA, Inc. | 8 | $163 |
| Johnson & Johnson | 7 | $153 |
| Epizyme, Inc. | 1 | $99 |
| Karyopharm Therapeutics Inc. | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Eisai Inc. | 3 | $64 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $48 |
| Gilead(2 entities) | 2 | $42 |
| Coherus Oncology, Inc. | 2 | $40 |
| Aadi Bioscience, Inc. | 2 | $37 |
| Array Biopharma Inc | 3 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Bayer | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Dova Pharmaceuticals | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Morphosys, US Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,331 in reported general payments places this provider in the 55th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 18 | $243,960 |
| Letrozole | 73 | $2,234 |
| Ondansetron OdtOndansetron | 48 | $800 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $498 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $464 |
| Prochlorperazine Maleate | 23 | $383 |
| Nystatin | 11 | $155 |
| Prednisone | 14 | $122 |
| Allopurinol | 13 | $121 |
| Tramadol Hcl | 16 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Goshen
- Ebenezer KioGoshen$40K
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.